Literature DB >> 32701386

Disparities in human papillomavirus (HPV) vaccine initiation and completion based on sexual orientation among women in the United States.

Eric Adjei Boakye1,2, Nosayaba Osazuwa-Peters3,4, Julia López5, Vy T Pham3, Betelihem B Tobo6, Leping Wan7, Mario Schootman8, Jane A McElroy9.   

Abstract

OBJECTIVES: We compared HPV vaccine initiation and completion of heterosexual with lesbian and bisexual (LB) women.
METHODS: We aggregated National Health and Nutrition Examination Survey data from 2009 to 2016 for 3,017 women aged 18 to 34 y in the United States. HPV vaccine initiation was defined as reported receipt of ≥1 dose of the vaccine and completion as receipt of the three recommended doses. Weighted percentages and multivariable logistic regression models were used to examine differences in HPV vaccine initiation and completion between heterosexual and LB women.
RESULTS: Approximately 12% of respondents self-identified as LB women. Overall, a higher percentage of respondents (26%) had initiated the HPV vaccine than completed the three vaccine doses (17%). In the bivariate analysis, LB women had higher initiation ([35% of LB women versus 25% heterosexual]; p = .0012) and completion rates ([24% of LB women versus 17% heterosexual]; p = .0052) than heterosexual women. After adjusting for covariates, compared to heterosexual women, LB women were 60% (aOR = 1.60, 95% CI: 1.16-2.19) more likely to initiate and 63% (aOR = 1.63, 95% CI: 1.12-2.37) more likely to complete the HPV vaccine.
CONCLUSIONS: Although LB women had higher likelihood of HPV vaccine initiation and completion compared with heterosexual women, their HPV vaccine uptake was well below the Healthy People 2020 target (80%). Understanding differences in the drivers of vaccine uptake in the LB population may inform strategies that would further increase HPV vaccine uptake toward achieving the 80% completion target.

Entities:  

Keywords:  HPV vaccination initiation and completion; HPV vaccine; Human papillomavirus; lesbian and bisexual women; sexual orientation; young adults

Mesh:

Substances:

Year:  2020        PMID: 32701386      PMCID: PMC7899676          DOI: 10.1080/21645515.2020.1778407

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  34 in total

1.  Sexual orientation disparities in Papanicolaou test use among US women: the role of sexual and reproductive health services.

Authors:  Madina Agénor; Nancy Krieger; S Bryn Austin; Sebastien Haneuse; Barbara R Gottlieb
Journal:  Am J Public Health       Date:  2013-12-12       Impact factor: 9.308

2.  Reproductive health screening disparities and sexual orientation in a cohort study of U.S. adolescent and young adult females.

Authors:  Brittany M Charlton; Heather L Corliss; Stacey A Missmer; A Lindsay Frazier; Margaret Rosario; Jessica A Kahn; S Bryn Austin
Journal:  J Adolesc Health       Date:  2011-06-08       Impact factor: 5.012

Review 3.  Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials.

Authors:  M Arbyn; L Xu
Journal:  Expert Rev Vaccines       Date:  2018-11-29       Impact factor: 5.217

4.  A Comparison of Parent- and Provider-Reported Human Papillomavirus Vaccination of Adolescents.

Authors:  Eric Adjei Boakye; Betelihem B Tobo; Nosayaba Osazuwa-Peters; Kahee A Mohammed; Christian J Geneus; Mario Schootman
Journal:  Am J Prev Med       Date:  2016-11-24       Impact factor: 5.043

5.  Sexual practices, risk perception and knowledge of sexually transmitted disease risk among lesbian and bisexual women.

Authors:  Jeanne M Marrazzo; Patricia Coffey; Allison Bingham
Journal:  Perspect Sex Reprod Health       Date:  2005-03

6.  Sexual orientation and sexual and reproductive health among adolescent young women in the United States.

Authors:  Samantha L Tornello; Rachel G Riskind; Charlotte J Patterson
Journal:  J Adolesc Health       Date:  2013-10-22       Impact factor: 5.012

7.  Risk of subsequent malignant neoplasms after an index potentially-human papillomavirus (HPV)-associated cancers.

Authors:  Maggie Wang; Arun Sharma; Nosayaba Osazuwa-Peters; Matthew C Simpson; Mario Schootman; Jay F Piccirillo; Warner K Huh; Eric Adjei Boakye
Journal:  Cancer Epidemiol       Date:  2019-12-06       Impact factor: 2.984

Review 8.  HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women.

Authors:  Maura L Gillison; Anil K Chaturvedi; Douglas R Lowy
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

9.  Prophylactic HPV vaccination and anal cancer.

Authors:  Elizabeth A Stier; Nagasudha L Chigurupati; Leslie Fung
Journal:  Hum Vaccin Immunother       Date:  2016-03-02       Impact factor: 3.452

10.  Vaccination differences among U.S. adults by their self-identified sexual orientation, National Health Interview Survey, 2013-2015.

Authors:  Anup Srivastav; Alissa O'Halloran; Peng-Jun Lu; Walter W Williams; Sonja S Hutchins
Journal:  PLoS One       Date:  2019-03-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.